Wuxi Pharmatech: (NYSE: WX)

$20.43

0.11 (0.54%)

Volume 360,920

May 17 04:01 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		20.08 - 20.48
	
		52wk Low - High
		13.00 - 21.14
	
		Previous Close
		20.32
	
		Avg. Volume
		425,441
	
		Industry
		MED-DRUGS
	
		Market Cap
		1.43 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.72
	
		PE (Forward)
		15.52
	
		Current Year Est.
		1.32
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		88 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            15.52
                        
                            PEG Ratio
                            1.32
                        
                            Current Year Est.
                            1.32
                        
                            Current Quarter Estimate
                            0.34
                        
                            Most Accurate Estimate
                            0.34
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-12-2013
                        
                            EPS Last Year
                            1.21
                        
                            Expected Earnings Growth
                            11.79%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use.   
Full WX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
WX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.34	0.32	1.32	1.47
Number of Estimates	5	5	6	6
Low Estimate	0.32	0.30	1.30	1.41
High Estimate	0.35	0.34	1.35	NA
Year Ago EPS	0.28	0.30	1.21	1.32
EPS Growth	20.71%	6.67%	8.82%	11.77%

More WX Estimates

Average Earnings Estimates for WX

EPS Growth for WX

Industry Analysis

Name	Symbol	Previous Close
WUXI PHARMATECH	WX	20.43
JAZZ PHARMACEUT	JAZZ	58.36
SALIX PHARM-LTD	SLXP	59.28
SANTARUS INC	SNTS	21.91
USANA HLTH SCI	USNA	65.46
BIOCRYST PHARMA	BCRX	1.71
CATALYST PHARMA	CPRX	0.83
CELL THERAPEUT	CTIC	1.16
CUBIST PHARM	CBST	49.51
ELAN CP PLC ADR	ELN	11.67

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Wider-than-Expected Loss at ChemoCentryx

May 14, 2013

Dendreon Narrows 1Q Loss

May 10, 2013

Good News for Cubist Pharmaceuticals

May 09, 2013

Narrower-than-Expected Loss at ArQule

May 09, 2013

Wider-than-Expected Loss at Corcept

May 07, 2013

Valeant Misses Earnings and Revenue Estimate in 1Q (Revised)

May 07, 2013

The Zacks Analyst Blog Highlights: Chicago Bridge & Iron, Shire, Actavis, UCB and WuXi PharmaTech

May 02, 2013

Shire Settles Lawsuit with Actavis

May 01, 2013

More WX Zacks Commentary

Financials

EPS TTM	1.21
Sales	500
Net Income	87
Price/Earnings	16.88
Price/Book	2.47
Price/Cash Flow	11.04
Price/Sales	2.78

More WX Financials

News

Shares of WuXi PharmaTech Cayman Have Risen Above Previous 52-Week High - Financial News Netwfork Online - 52-Week High-Lows

May 15, 2013

Top 3 Companies in the Life Sciences Tools & Services Industry With the Lowest P/E Ratio (CBM, A, WX) - Financial News Network Online - News Corner

May 15, 2013

VTG, WX, CPHI, TYPE, ITA, CTGX Are Seasonally Ripe To Go Down In the Next Five Weeks - M2

May 15, 2013

WuXi PharmaTech Beats on Both Top and Bottom Lines - TheMotleyFool

May 15, 2013

*XH WuXi PharmaTech Q1 net profits up 3.4 pct to 21.7 mln USD - Xinhua Economic News

May 14, 2013

UPDATE: Bank of America Raises PO on WuXi PharmaTech After Strong 1Q13 Report - Benzinga

May 14, 2013

UPDATE: Jefferies Raises PT on WuXi PharmaTech on Great Start to 2013 - Benzinga

May 14, 2013

UPDATE: Oppenheimer Raises PT on WuXi PharmaTech Following Strong 1Q13 Results - Benzinga

May 14, 2013

See All News Stories on WX

Broker Recommendations

Current ABR	1.27
ABR (Last Week)	1.27
# of recs in ABR	11
Average Target Price	22.71
Industry Rank by ABR	88 out of 265
Rank in Industry	5 out of 91

More WX Broker Recommendations

Day Low - High	20.08 - 20.48
52wk Low - High	13.00 - 21.14
Previous Close	20.32
Avg. Volume	425,441
Industry	MED-DRUGS
Market Cap	1.43 B
Div - Yield	0.00 - 0.00
Beta	1.72
PE (Forward)	15.52
Current Year Est.	1.32
Quarterly Earnings ESP	0.00%

PE (Forward)	15.52
PEG Ratio	1.32
Current Year Est.	1.32
Current Quarter Estimate	0.34
Most Accurate Estimate	0.34
Earnings ESP	0.00%
Next Earnings Report Date	08-12-2013
EPS Last Year	1.21
Expected Earnings Growth	11.79%

Username: Password:

Remember me [?]

Wuxi Pharmatech: (NYSE: WX)

$20.43

0.11 (0.54%)

Volume 360,920

May 17 04:01 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations